DBV Technologies SA (DBVT)
0.7831
+0.02
(+2.88%)
USD |
NASDAQ |
Nov 04, 16:00
0.7831
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies Research and Development Expense (Annual): 60.22M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 60.22M |
| December 31, 2022 | 75.54M |
| December 31, 2021 | 70.34M |
| December 31, 2020 | 101.61M |
| December 31, 2019 | 115.10M |
| December 31, 2018 | 122.59M |
| December 31, 2017 | 126.25M |
| Date | Value |
|---|---|
| December 31, 2016 | 82.90M |
| December 31, 2015 | 37.43M |
| December 31, 2014 | 25.71M |
| December 31, 2013 | 23.98M |
| December 31, 2012 | 15.21M |
| December 31, 2011 | 8.652M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
60.22M
Minimum
2023
115.10M
Maximum
2019
84.56M
Average
75.54M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Edap TMS SA | 7.538M |
| Genfit SA | 50.57M |
| Cellectis SA | 87.65M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Akari Therapeutics PLC | 5.45M |